Positive Health Online

Abstract

SKROZA and COLLEAGUES, (1)Department of Dermatology "Daniele Innocenzi" Sapienza University of Rome, Polo Pontino, Rome, Italy - concetta.potenza@uniroma1.it conducted an open-label randomized controlled study to evaluate the role of a nutraceutical in addition to etanercept therapy for patients affected by psoriasis and metabolic syndrome.

Background

Psoriasis is a systemic inflammatory immune-mediated skin disease. Recently a relationship with metabolic syndrome in terms of psoriasis severity and response to therapy was observed.

Methodology

The authors performed an open-label randomized controlled study to evaluate the role of a nutraceutical containing Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E and selenium in addition to etanercept therapy [(Enbrel) a drug used for treating rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis] for patients affected by psoriasis and metabolic syndrome. Forty patients were enrolled and divided into two arms, one receiving only etanercept, one other receiving also the neutraceutical. After a period of 3 months (T1) a second evaluation of the considered parameters was performed.

Results

At T1 statistically significant differences were detected in HDL cholesterol and triglycerides values both comparing the two arms and in the nutraceutical arm.

Conclusion

Our results show that the dietary addiction of the nutraceutical to the etanercept therapy in patients affected by both psoriasis and metabolic syndrome could help to restore the normal lipid profile.

References

Skroza N(1), Proietti I, Bernardini N, La Viola G, Nicolucci F, Pampena R, Tolino E, Zuber S, Mancini MT, Soccodato V, Balduzzi V, Potenza C. Efficacy of food supplement to improve metabolic syndrome parameters in patients  affected by moderate to severe psoriasis during anti-TNFα treatment. G Ital Dermatol Venereol. 148(6):661-5. Dec 2013.